Context-specific molecular vulnerabilities that arise during tumor evolution represent an attractive intervention target class. However, the frequency and diversity of somatic lesions detected among lung tumors can confound efforts to identify these targets. To confront this challenge, we have applied parallel screening of chemical and genetic perturbations within a panel of molecularly annotated NSCLC lines to identify intervention opportunities tightly linked to molecular response indicators predictive of target sensitivity. Anchoring this analysis on a matched tumor/normal cell model from a lung adenocarcinoma patient identified three distinct target/response-indicator pairings that are represented with significant frequencies (6%-16%) in the patient population. These include NLRP3 mutation/inflammasome activation-dependent FLIP addiction, co-occurring KRAS and LKB1 mutation-driven COPI addiction, and selective sensitivity to a synthetic indolotriazine that is specified by a seven-gene expression signature. Target efficacies were validated in vivo, and mechanism-of-action studies informed generalizable principles underpinning cancer cell biology.
INTRODUCTION
Widespread evidence indicates that aberrant cancer cell-regulatory frameworks generate collateral vulnerabilities that can be exploited for therapeutic benefit. These vulnerabilities can be a consequence of oncogene addiction, gene-specific haploinsufficiencies, and other genetically and epigenetically derived fragilities in cell-regulatory systems (Jä nne et al., 2009; Luo et al., 2009; Muller et al., 2012) . The critical barrier confronting this opportunity, for many tumor types, is the extreme heterogeneity of the molecular etiology of neoplastic disease, which confounds annotation of effective context-selective intervention targets. For non-small-cell lung cancer (NSCLC), a tumor responsible for 1 million deaths/year, over 160 nonsynomous somatic mutations are detected per tumor, and the vast majority of these mutations are nonrecurrent (Cancer Genome Atlas Research Network, 2012; Imielinski et al., 2012) . Actionable mutations have been identified in epidermal growth factor receptor (EGFR) and EML4-ALK (Lynch et al., 2004; Soda et al., 2007) but are present in only 15% of lung adenocarcinomas (Imielinski et al., 2012) , whereas the majority of NSCLC patients are not associated with any known pharmaceutically addressable target. This missing coverage underscores the need to develop new target opportunities that are tightly linked to molecular response indicators.
To generate a testbed representative of the molecular heterogeneity of NSCLC, we assembled a panel of 91 lung tumorderived cell lines and 3 immortalized nontumorigenic airway epithelial cultures. Though limited by the sparse complexity of the tissue culture environment and therefore limited in the synthetic genetic and chemical interactions that can be observed, this cell-line panel has been shown to recapitulate genetic profiles found in tumors and to recapitulate selective responsiveness to molecularly targeted therapies (Gazdar et al., 2010; Sharma et al., 2010) . Beginning with a matched tumor/normal cell model from a single lung adenocarcinoma patient, 230,000 synthetic small molecules and two independent whole-genome arrayed small interfering RNA (siRNA) libraries were used to identify chemical and genetic perturbations selectively toxic to the patient's tumor cell line. These agents were then tested to identify perturbations that were innocuous to nontumorigenic cells but had activity in at least 30% of the NSCLC cell lines. The resulting toxicity patterns were correlated with genomic profiles to identify somatic mutations and expression signatures that predicted sensitivity or resistance to these perturbations. In this way, we identified three distinct target/response-indicator pairings. First, we found that NLRP3 mutations, which occur in 16% of lung adenocarcinomas, drive addiction to the antiapoptotic protein FLIP. The mechanism of action is through NLRP3-dependent chronic activation of inflammasome signaling, which sensitizes these cells to FLIP-dependent restraint of caspase-8-induced cell death. Second, we found that co-occurring mutations in KRAS and LKB1, present in 6% of lung adenocarcinoma patients, are sufficient to drive addiction to the coatomer complex I (COPI)-dependent lysosome acidification. This liability was determined to be a consequence of obligate supply of TCA-cycle substrates by lysosome-dependent consumption of extracellular macromolecules. Chemical inhibition of this process, with the natural product saliphenylhalamide A, inhibited KRAS mut /LKB1 mut tumor cell survival in vitro and in vivo. Finally, we found that selective sensitivity to a synthetic indolotriazine defines a subtype of NSCLC cells estimated to occur at a frequency of $10% of lung tumors. Indolotriazine sensitivity corresponded to selective activation of an endoplasmic reticulum stress response and can be effectively predicted using a seven-gene quantitative mRNA expression signature.
RESULTS

Public and Private Vulnerabilities in NSCLC
To begin to assess the diversity of selective vulnerabilities that can arise within lung cancer cell-autonomous regulatory contexts, we selected a matched tumor/normal pair (HCC4017/ HBEC30KT), derived from a 62-year-old female smoker with stage 1A adenocarcinoma, for extensive functional and genomic interrogation ( Figure 1A ). Authentic somatic mutations and copy number variation, in the tumor line as compared to normal cells, were identified from whole-exome hybridization-capture sequencing (1303 average read-depth; Table S1 and Data S1 available online). Two hundred and ninety-six nonsynonymous exonic single-nucleotide somatic variants were detected in HCC4017 ( Figure 1B ), 152 of which are predicted to be deleterious to protein function (Data S1). Copy number variation was extensive, as estimated by exon read-depth (Figures 1B and S1A) and SNP array ( Figure S1A ), and correlated with relative mRNA concentrations as determined by RNA sequencing (RNA-seq) (Data S2; Figure S1A ). Two whole-genome arrayed siRNA libraries and a collection of $230,000 chemical compounds were then screened to identify agents selectively toxic to HCC4017 versus HBEC30KT (Data S2 and S3) . A Z score cutoff of À3 was used to identify candidate HCC4017-selective siRNA sensitivities. This thresholding resulted in predominantly nonoverlapping sets of candidates from each siRNA library, presumably due to a combination of false-negative and false-positive relationships. As previously described (Jacob et al., 2011) , the former is at least partially an artifact of assigned selection thresholds. In direct support of this, the empirical cumulative distribution of the Z scores from siRNA pools in library 1, corresponding to ''hits'' from library 2, indicated a significant enrichment of activity as compared to the background distribution ( Figure S1B ). To defend against false positives, individual oligos were tested for each of the 326 nonredundant hits from the union of the two libraries together with a K-S statistic that predicts oligonucleotide seed sequence-specific activity that is independent of target depletion (Tables S2 and S3 ; Data S4). Eighty-five surviving siRNA pools that were reproduced in HCC4017 and also innocuous upon testing in HBEC30KT and two additional telomerase/ CDK4-immortalized nontumorigenic HBEC lines were then examined across a panel of 21 additional NSCLC cell lines (Data S5; Figures 1C and S1C) .
A striking feature of the response of the cell-line panel to the siRNA collection was the largely idiosyncratic activity pattern ( Figure 1C) . Forty percent of the tested siRNAs had measurable consequences on the viability of 10% or less of the cell-line panel, and no single siRNA pool was identified with activity in over 90% of the panel (Data S5; Figure 1C ). Manual curation of the biological processes served by the siRNA target genes indicated an enrichment of signal transduction machinery and transcription factors within the ''private'' target class and an enrichment of housekeeping machines (cell-cycle control, mRNA splicing, ribosomal proteins, and vesicle trafficking) within the ''public'' target class (Data S6; Figure 1D ). Among the private targets, small-molecule inhibition of USP8 (Gué dat and Colland, 2007) largely recapitulated the selectivity of siRNA-mediated USP8 depletion, suggesting bona fide selectivity ( Figure S1D ). We found significant correlation of the private target class of HCC4017-sensitive siRNAs with low-target gene expression, suggesting that the private nature of some targets may be at least partially a consequence of expression bias ( Figure S1E ). As a whole, siRNA targets were recovered evenly from all genomic loci with the exception of homozygously deleted regions where, as expected, none were located (Figures 1B and S1F) . However, a slightly larger number of hits (CACNA2D4, POM121L12, TMEM106B, BZW2, RBBP9, HBA1, NUPL2, SDK1, VSTM2A, C16orf54, and CYC1) were identified from amplified and overexpressed loci as compared to the rest of the genome (Figures S1F and S1G) . A first-degree interaction network was constructed to identify potential coherent relationships among HCC4017-selective targets and the somatic mutations detected within that cell line ( Figure S1H ). Though verifiable and informative relationships were detected (Figures S1I and S1J), direct connections to somatic variation appear insufficient to account for the high frequency of private vulnerabilities identified within this cell line.
Context-Selective FLIP Addiction
We prioritized relationships found in at least 30% of the NSCLC panel to afford an opportunity for codetection of genetic response indicators. Depletion of CFLAR, which encodes the catalytically inactive caspase-8 analog FLIP (Irmler et al., 1997) , was sufficient to markedly induce apoptosis in HCC4017 cells and was toxic to multiple additional NSCLC lines as compared to nontumorigenic bronchial epithelial cells (Data S5; Figure S1C ). Cell lines from the two tails of the toxicity profile, derived from testing CFLAR depletion in 22 NSCLC lines, were selected for interrogation of molecular features correlating with sensitivity to CFLAR depletion (Figure 2A ). From whole-genome mRNA expression profiles, PYCARD, IFIT2, and IFIT3 were identified as the top-ranked genes commonly upregulated in CFLARdependent versus CFLAR-independent cell lines ( Figure 2A , bottom panel). This expression model was sufficient to predict additional CFLAR-dependent cell lines from an unsupervised hierarchical cluster of a panel of 34 lines outside the original discovery set ( Figure S2A ). FLIP restrains execution of programmed cell death pathways through direct suppression of caspase-8 (Tschopp et al., 1998) . FLIP addiction, therefore, infers the presence of latent death signals that are released upon removal of prosurvival restraints. This scenario is akin to the selective sensitivity of cancer cells to chemical mimics of SMAC (second mitochondria-derived activator of caspase) in the presence of tumor necrosis factor (TNF)-dependent apoptotic signaling, which is the consequence of uncoupling inhibitor of apoptosis proteins (IAPs) from otherwise active caspases (Tenev et al., 2011) . However, only two of seven FLIP-dependent cell lines examined were Figure S1H ) are displayed in the boxes. See also Figure S1 , Tables S1, S2 , and S3, and Data S1, S2, S4, S5, and S6. 
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Sensitivity to SMAC mimetic S: < 0.5μM R: > 5μM See also Figure S2 and Table S4. additionally sensitive to SMAC-mimetic exposure, suggesting that FLIP can restrain programmed cell-death signals independently of SMAC-responsive IAPs ( Figure 2A ; Table S4 ). FLIP dependence did not correlate with expression of FLIP, its prodeath partner caspase-8, or SMAC-mimetic-resistant IAP2 (Petersen et al., 2010) ( Figure S2B ). However, sensitivity to FLIP depletion was completely reversed upon caspase-8 codepletion ( Figure 2B ). In contrast, SMAC-mimetic sensitivity was minimally affected by caspase-8 depletion and completely reversed by depletion of RIP1 kinase, an initiator of ripoptosome assembly that is negatively regulated by IAPs (Feoktistova et al., 2011; Tenev et al., 2011) (Figure 2C ). Rescue of FLIP addiction by depletion of individual core components of the ripoptosome, or other canonical-death-pathway activators implicated in cancer, was cell line selective ( Figure 2B ). This suggests multiple distinct regulatory contexts within the NSCLC panel converge on FLIPdependent restraint of caspase-8-initiated cell death. By its nature, the PYCARD, IFIT1, IFIT2 expression signature is serving as a common indicator of these distinct contexts ( Figure 2A ). IFIT1 and 2 are primary response genes induced by interferon and may ordinarily mediate cytotoxic responses to pathogen detection (Wathelet et al., 1988) . PYCARD encodes ASC, a component of the inflammasome whose expression is also responsive to inflammasome activation signals (Masumoto et al., 2006; Strowig et al., 2012) . Of note, HCC4017 harbors a somatic nonsense mutation in the inflammasome component NLRP3 located in the linker region between the N-terminal NACHT domain and C-terminal leucine-rich repeat (LRR) domain (p.Y591*, Figure 2D ). This alteration is predicted to encode a truncated, constitutively active protein, due to loss of LRR-domainmediated repression of the NACHT domain (Hu et al., 2013) . Derepression of NACHT domains promotes promiscuous NALP oligomerization and interaction with CARD domain proteins like ASC (Strowig et al., 2012) . Somatic exonic NLRP3 mutations are present in 16% of lung adenocarcinomas ( Figure S2C , 21/ 129 in the LUAD TCGA samples) (Cerami et al., 2012) , and NLRP3 mutant adenocarcinomas were significantly enriched for NF-kB activity ( Figure S2D ), suggesting that NLRP3 mutations in this context may be gain-of-function alterations. In support of this, highly deleterious mutations in NLRP3 are significantly associated with PYCARD overexpression within the TCGA adenocarcinoma data set ( Figure 2E ), and there is an overall significant positive correlation between PYCARD and NLRP3 expression ( Figure S2E ). Targeted sequencing revealed an analogous nonsense mutation in the FLIP-dependent cell line HCC15 (p.E401*) and a missense mutation in the FLIP-dependent cell line HCC366 (p.S727Y) (Barretina et al., 2012) . Importantly, like caspase-8, codepletion of NLRP3 relieved sensitivity of NSCLC lines to FLIP depletion, suggesting that NLRP3 activity helps drive FLIP addiction ( Figure 2F ). Furthermore, NLRP3 mutation status was significantly associated with sensitivity to FLIP depletion ( Figure S2F ), and two additional NLRP3 mutant NSCLC lines, identified from outside of the original tested panel, were also FLIP dependent ( Figure S2G ).
To model conservation of FLIP addiction within a tumorigenic context, we assessed the effects of CFLAR knockdown in a mouse xenograft model. Two weeks following subcutaneous injection of HCC15 cells, mice were randomly divided and treated with siRNAs incorporated into DOPC nanoliposomes (intraperitoneal [i.p.] administration) according to the following treatment groups (n = 10/group): control siRNA/DOPC and CFLAR siRNA/DOPC for 4 weeks. In comparison to the control siRNA group, tumors from the CFLAR siRNA group had a 87.2% reduction in tumor mass (p = 0.026; Figure 2G ). These cumulative observations indicate that FLIP may represent an intervention opportunity in lung cancer linked to enrollment biomarkers that include NLRP3 mutation status.
KRAS/LKB1 Mutation Status Specifies Coatomer 1 Addiction
Next, the mutation statuses for five recurrently mutated genes (TP53, CDKN2A, KRAS, STK11 [LKB1], NRAS), collected by targeted sequencing, were queried for association with each of 85 siRNA toxicity profiles (Table S1 ; Data S5). Of note, co-occurrence of KRAS/LKB1 mutations was significantly associated with sensitivity to depletion of COPI subunits ARCN1, COPB1, and COPA ( Figure S3A ). Approximately 6% of lung adenocarcinoma patients have co-occurring KRAS/LKB1 mutations (Imielinski et al., 2012) . COPI participates in retrograde transport, is required for endosome maturation (Huotari and Helenius, 2011; Razi et al., 2009) , and is a CDC42 effector required for CDC42 transformation (Wu et al., 2000) . From the intersection of the first-degree interaction network of HCC4017-essential genes ( Figure S1H ) and the commonality of responsiveness with the larger NSCLC cell-line panel ( Figures 1C and 1D ), we identified a total of five of seven components of the COPI. NSCLC cell lines representing the two tails of the distribution of sensitivity to COPI subunit depletion are shown in Figure 3A . Inhibition of COPI expression in multiple telomerase-immortalized bronchial epithelial cells was relatively innocuous and comparable to the consequence of COPI depletion in the COPI-resistant cancer lines ( Figures 3A and 3B ). Sensitivity to COPI depletion was recapitulated in soft-agar colony formation assays ( Figure 3C ). To assess the therapeutic utility of targeting the COPI subunit ARCN1, we utilized an orthotopic lung adenocarcinoma model capable of spontaneous metastasis. One week after surgical introduction of A549 cells into the left lung, mice were randomly divided and treated with siRNAs incorporated into DOPC nanoliposomes (i.p. administration) according to the following treatment groups (n = 10/group): control siRNA or ARCN1 siRNA for 5 weeks. Treatment with ARCN1 siRNAs led to substantial reductions in primary tumor size (92.9% by volume, p = 0.0087; 51.3% by left lung mass, p = 0.0032) as well as metastastic burden (90.4% reduction, p = 0.0015) (Figures 3D and S3B) . This sensitivity correlated with hypophosphorylation of Rb and induction of cell-cycle arrest and apoptosis in vitro ( Figures S3C and S3D ). HCC4017 was an outlier with respect to LKB1 mutation status; however, this line has a defective AMPK response and therefore is the functional equivalent of COPI-addicted cell lines with compound lesions in KRAS and LKB1 ( Figure 3E ). Importantly, co-occurrence of KRAS and LKB1 mutations was a robust predictor of COPI addiction when tested in NSCLC cell lines outside the original discovery panel ( Figure 3F ), and LKB1 depletion was sufficient to sensitize KRAS mutant/LKB1 wild-type cell lines to COPI depletion ( Figure 3G ). Oncogenic KRAS together with LKB1 Loss Is Sufficient to Induce COPI Addiction To evaluate the sufficiency of compound KRAS and LKB1 perturbation for induction of COPI addiction, we engineered a series of HBEC30KT derivatives with stepwise stable suppression of p53, stable expression of KRAS
G12V
, and stable suppression of LKB1 ( Figures 4A, S4A , and S4B). Among these, only the final derivative was tumorigenic in immune-compromised mice, and tumors presented with mixed adeno/squamous characteristics ( Figure 4B ). This mixed morphology is strikingly similar to that observed in spontaneous mouse lung tumors that arise as a consequence of Kras G12V expression in an Lkb1 null background (Ji et al., 2007) . A screen of 85 siRNA pools corresponding to the HCC4017-essential genes, within the HBEC30KT isogenic progression series, revealed acquired vulnerability to 17 targets within the KRAS mut /LKB1 mut background ( Figure 4C ).
Sensitivity to depletion of these same 17 genes was significantly enriched in KRAS mut /LKB1 mut NSCLC cell lines as compared to that in other NSCLC lines tested ( Figure 4D ). COPI subunits were present in this context, indicating that KRAS mut /LKB1 mut status is sufficient to specify COPI addiction ( Figure 4E ). (Table   S5 ; Figure S5A ; nominal p < 0.01), though none of these (E) The indicated cells were stained with crystal violet as in Figure 3B . Immunoblot indicates persistence of target depletion in resistant cells at the 8 day time point. See also Figure S4 .
signatures cleanly segregated the two classes. An siCOPI toxicity-associated gene-expression signature, with bimodal distribution, returned a more focused separation centered on chemokines and cytokines ( Figure S5B , FDR < 0.001) reminiscent of the oncogenic RAS-induced secretory senescence phenotype (Coppé et al., 2008) . Remarkably, 30% of the top 100 most differentially expressed genes, as defined by signalto-noise ratio, intersected the molecular classification signature for the mesenchymal, or ''claudin-low,'' subtype of triple-negative breast cancer (Prat et al., 2010 ) ( Figure 5A , hypergeometric p < 6.7 3 10 À16 ). Consistent with this, we found that three ''claudin-low'' breast cancer cell lines (Prat et al., 2010) were sensitive to COPI depletion as compared to cell lines corresponding to the lumenal A or basal A subtypes ( Figure 5B ). The mesenchymal subtype of triple-negative breast cancer is an aggressive metastatic disease enriched with self-renewing tumor-initiating cells (Prat et al., 2010) . Dichotomization of 272 molecularly and clinically annotated lung tumor samples, using the expression signature defined by COPI addiction, revealed significantly reduced overall survival and disease-free survival for patients harboring signature-positive tumors ( Figures 5C  and S5C ). Importantly, this relationship was reproducible with an independent patient cohort and data set ( Figure S5D ).
To parse molecular correlates that may provoke COPI addiction, we employed a focused suppressor screen that queried genes and pathways enriched in the COPI-sensitive cell lines (Figures S5E and S5F ; see Experimental Procedures for rationale). The most significant interaction recovered was interleukin-6 (IL-6) pathway activation ( Figure S5E ). IL-6 secretion was significantly elevated in the COPI-sensitive lung and breast cancer cell lines, including the HBEC30KT progression series ( Figures S5G, S5H , and S5I). Oncogenic RAS expression was sufficient to induce IL-6 production; however, co-occurring loss of LKB1 signaling enhanced this phenotype in human epithelial cells and in mouse tumors ( Figures S5I, S5J , and S5K). Inhibition of IL-6 signaling by IL-6 depletion, IL-6R depletion, or Let-7 expression significantly suppressed COPI addiction ( Figures 5D, 5E , 5F, and S5L).
IL-6 has been characterized as a RAS-responsive cytokine that promotes tumorigenesis in a paracrine fashion by provoking stromal remodeling of the tumor microenvironment (Coppé et al., 2008) . Consistent with this, we found that IL-6 secretion was KRAS dependent in COPI-addicted cell lines ( Figure 5G) . Furthermore, the tryptophan metabolism expression signature associated with COPI-addicted (KRAS mut /LKB1 mut ) cell lines ( Figure S5A ) implicated aryl hydrocarbon receptor (AhR) signaling as a mechanism that may contribute to IL-6 production. AhR induces IL-6 production in metastatic glioma, and both kynurenine and kynurenic acid, produced during tryptophan synthesis, serve as endogenous AhR ligands (Opitz et al., 2011) . Consistent with this, depletion of AhR or the AhR nuclear translocator (ARNTL) significantly reduced IL-6 secretion (Figure 5H ). Taken together, these observations suggest that selection for IL-6 secretion within the tumor microenvironment has collateral consequences on tumor cell biology that provoke addiction to COPI function. COPI activity thus becomes a collateral vulnerability that, if targetable, may represent a precision intervention opportunity. (Jeon et al., 2012; Son et al., 2013) . This presents a compelling mechanistic scenario whereby KRAS mut /LKB1 mut cells are selectively sensitized to perturbations that impair reduction of reactive oxygen. In contradiction to this expectation, we found that glutathione or N-acetyl cysteine failed to rescue COPI addiction and were instead individually toxic ( Figure S5F) . Furthermore, the free radical scavenger NDGA displayed synthetic toxicity to KRAS mut /LKB1 mut expression in the HBEC30KT background, consistent with the reported prosurvival role of reactive oxygen within the context of oncogenic RAS expression ( Figure S6A ) (Irani et al., 1997) .
To help uncover the mechanistic basis of COPI addiction, we assembled a panel of chemical probes that (1) intersect biological processes coupled to COPI function, (2) inhibit signaling pathways dysregulated in the KRAS mut /LKB1 mut background, or (3) engage cell-stress responses predicted to be induced by COPI depletion. The dose-dependent toxicity response to these compounds was then measured across 20 cell lines. Within this panel, the vacuolar ATPase inhibitor bafilomycin A1 (bafA) was discovered to have significant selective toxicity against the KRAS mut /LKB1 mut cell lines ( Figure 6A ) independent of ROS ( Figures S6B and S6C ). Like COPI depletion, exposure to 50 nM bafA for 48 hr induced CDKI accumulation, Rb hypophosphorylation, and caspase activation ( Figure S6D ). This suggests that KRAS mut /LKB1 mut cells may be selectively dependent upon lysosomal maturation, which is itself dependent upon COPI complex activity (Huotari and Helenius, 2011; Razi et al., 2009 Figure S6E ). Furthermore, gain of COPI dependency through LKB1 depletion in a KRAS mutant NSCLC line, H2009, was coupled to the accumulation of the lysosomal membrane protein LAMP2 (Figure S6F) Figure S6H) . A gene-expression feature (topranked GO term by GSEA) associated with COPI dependency and KRAS mut /LKB1 mut status was the enrichment of energy derivation by oxidation (Table S5 ; Figure S6I ). Related to this, we noted that COPI depletion, exposure to bafA, or exposure to a structurally distinct vATPase inhibitor, saliphenylhalamide A (saliPhe) (Lebreton et al., 2008) , resulted in the concomitant appearance of dysmorphic mitochondria in KRAS mut /LKB1 mut cells ( Figures 6B and 6C ) but not in bafA-resistant cells (Figure S6J ). This altered morphology corresponded to reduced oxygen-consumption rates together with increased extracellular A549  H460  H157  HCC4017  HCC44  H441  H1975  H1819  H2009  H2882  HCC15  HCC461  HCC366 Figure S5C . p values are log-rank test.
(legend continued on next page) acidification rates, suggesting impaired oxidative phosphorylation and concomitant induction of glycolysis ( Figures 6D and  S6K ). However, this mitochondrial dysfunction was not coupled to loss of mitochondrial membrane potential ( Figure S6L ). Rather, bafA and saliPhe inhibited incorporation of heavy carbons from 13 C-labeled glucose or glutamine into citrate, consistent with inhibition of the mitochondrial TCA cycle ( Figure 6E ). Perhaps through a futile adaptive response, loss of TCA-cycle activity was paralleled by increased glucose and glutamine consumption concomitant with conversion to secreted lactate and glutamate ( Figures S6M and S6N ). This phenotype was also observed in response to COPI depletion ( Figure S6O ). Finally, we found that direct inhibition of vATPase assembly by ATP6V1B2 depletion was sufficient to prevent lysosomal acidification ( Figure 6F ) and inhibit mitochondrial respiration (Figure 6G ). These observations indicate that lysosomal maturation is selectively required to support mitochondrial function in KRAS mut /LKB1 mut cells. The coupling of this vulnerability to a genetic background that promotes energetic stress led us to consider the possibility that KRAS mut /LKB1 mut cells are selectively dependent upon hydrolysis of lysosomal macromolecules for supply of mitochondrial TCA-cycle substrates. We found that delivery of cell-permeable pyruvate (methyl pyruvate, MP) or a-ketoglutarate (dimethyl-2-oxoglutarate, MOG), two major carbon sources fueling the mitochondrial TCA cycle, rescued cell viability and mitochondrial respiration in the presence of bafA ( Figures 6H and S6P) . Importantly, this rescue occurred without restoration of lysosomal acidification ( Figure S6Q ), consistent with the hypothesis that lysosomes support mitochondrial function through supply of an obligate nutrient source in KRAS mut / LKB1 mut cells. Perdurant acetyl-CoA carboxylase activity in the KRAS mut /LKB1 mut background is likely a mechanism that helps drive lysosomal addiction, as ACC1 depletion rescued cell viability in the presence of bafA ( Figure 6I ). We suspect that ACC1 inactivation is facilitating productive fatty-acid betaoxidation as an alternate energy source due to depletion of malonyl-coA, an ACC1 product that inhibits mitochondrial import of long-chain fatty acids (Abu-Elheiga et al., 2001) . These observations present a compelling argument for consideration of lysosomes as a metabolic bottleneck by which to target energy homeostasis in KRAS mut /LKB1 mut lung cancer cells. To model this in vivo, mice bearing established HCC4017 subcutaneous xenografts were exposed to saliPhe (12.5 mg/kg/day, n = 5) or vehicle (n = 4) using osmotic pumps implanted i.p. The pumps eluted drugs for $17 days, at which time tumors in the vehicletreated group were 174% larger, whereas tumors in the saliPhe-treated animals were 40% of the starting volume. The effect of saliPhe was durable as tumors were allowed to grow for an additional 35 days in the absence of further drug exposure, and tumors in saliPhe-treated animals were 4-fold smaller than tumors in vehicle-treated animals (0.116 ± 0.27 g versus 0.46 ± 0.13 g; p < 0.05) ( Figure 6J) .
A Gene-Expression Model Predicts Sensitivity to a Synthetic Compound, Indolotriazine
To collect additional chemical probes for detection of subtypeselective vulnerabilities in NSCLC, we examined 352 compounds (out of 230,000 screened) that were selectively toxic to HCC4017 cells versus HBEC30KT at 2.5 mM ( Figure S7A ; Data S3-1 and S3-2). Two of the 352 compounds displayed bimodal LD50s across 12 NSCLC lines (>3-fold separation of ''sensitive'' versus ''resistant'' lines). Among these, an indolotriazine, SW044248, was selectively toxic in 18/74 NSCLC lines and innocuous up to the highest testable dose in four different telomerase-immortalized bronchial epithelial cell lines ( Figure 7A ; Data S3-3). To inform the mode of action, resistant HCC4017 subclones were isolated following long-term exposure to the compound. RNA-seq identified differential gene-expression responses to SW044248, in parental versus resistant HCC4017 variants, corresponding to a strong and selective ER stress-response signature ( Figure 7B ; Data S7) (Hetz, 2012) . Consistent with this, CHOP and IRE1a were robustly induced within 24 hr of exposure to SW044248 ( Figure 7C ). This response was uniform among the SW044248-sensitive NSCLC lines but absent in resistant lines ( Figure 7D ). The latter is most likely a consequence of selective vulnerability rather than selective exposure as equivalent SW044248 accumulation and stability were observed in both sensitive and resistant cell lines as detected by gas chromatography-mass spectrometry (GC-MS) ( Figures S7B and S7C) .
To identify features that may predispose to the indolotriazine sensitivity, we searched for gene-expression networks that correlated with the compound responsiveness within the cell-line panel. Two ER stress-related networks were ranked among the top discoverable networks by edge flux (EF) and process flux (PF) values ( Figure S7D ) (Komurov et al., 2012) . In addition, an elastic net regression model using basal gene-expression data identified seven genes (C8G, PSG7, ACOT6, DEPDC5, MMP16, UBR1, and CYP4F22) as robust indicators of indolotriazine responsiveness (Figures 7E and S7E ). Feature performance was filtered by a 2003 bootstrapping protocol, from which all features were detected at frequencies > 50%. The sum of the weighted features in this model were used to predict SW044248 sensitivity from a panel of 38 NSCLC lines outside of the training set. HCC2429 and H1770 represented the two tails (sensitive and resistant) of the distribution of predicted IC 50 s, which were empirically validated with eight-point dose-response curves (Figure 7F) . Twenty-three of 231 lung adenocarcinomas were within the left-hand tail of the frequency distribution of elastic net scores, suggesting that $10% of tumors contain expression features consistent with SW044248 sensitivity ( Figure S7F ). See also Figure S5 and Table S5 . therapeutic intervention opportunities. Starting from within the context of a single lung adenocarcinoma patient, we identified genetic and chemical vulnerabilities selectively associated with tumorigenicity. However, the incidence of these vulnerabilities, within a lineage-restricted panel of NSCLC-derived cell lines, was highly idiosyncratic. By focusing on perturbations with significant activity in a large cell-line panel, we could begin to detect intervention targets linked to molecular subtypes that specify target sensitivity and have reasonable frequencies of representation within the lung cancer patient population. A robust, but previously unrecognized, genotype/phenotype relationship uncovered by this approach is the selective addiction of NLRP3 mutant cells to FLIP. FLIP is widely recognized as a candidate oncology target opportunity due to its role in deflection of caspase-8-dependent programmed cell death (Safa and Pollok, 2011) , but distinct genetic settings that specify FLIP dependence had not been elaborated. NLRP3 triggers inflammasome assembly and consequent activation of NF-kB and cytokine production upon detection of microbial infection or cellular injury (Bryant and Fitzgerald, 2009; Manji et al., 2002) . It is constitutively expressed in epithelial cells but, in the absence of ''danger signals,'' is thought to exist in an autoinhibited state (Hu et al., 2013) . Of note, mutations in NLRP3 result in persistent cytokine production and are the causal lesions for CAPS, a group of congenital autoinflammatory diseases (Hoffman et al., 2001 ). In light of NLRP3's role in innate immune signaling, it is reasonable to suspect that the frequent NLRP3 alterations found in lung tumors could contribute to tumor growth by inflammatory signal-mediated recruitment of stromal cell populations. In this scenario, positive selection for NLRP3 variants that stimulate production of a protumorigenic niche creates a collateral dependence on FLIP inhibition of apoptosis. The mechanistic coupling may be direct given recent observations that the NLRP3 inflammasome can bind and activate caspase-8 (Gringhuis et al., 2012; Pierini et al., 2012; Sagulenko et al., 2013) . Direct chemical inhibition of FLIP is not currently available; however, a variety of small molecules that inhibit FLIP expression or enhance FLIP degradation have been reported (Safa and Pollok, 2011; Zhao et al., 2011) and may represent a path forward for pharmacological targeting of NLRP3 mutant lung cancers.
Detection of oncogenic KRAS-linked vulnerabilities is a highpriority, but often confounding, pursuit in multiple neoplastic settings because of the frequency of representation of this oncogene in human tumors. Within the context of NSCLC cells, loss of LKB1 activity together with expression of oncogenic KRAS is required and sufficient to drive COPI addiction. This genetic interaction reinforces the notion that all KRAS cancers are not equivalent, and robust mapping of intervention opportunities must account for distinct collaborative alterations that result in distinct collateral vulnerabilities. COPI participates in a variety of dynamic membrane-trafficking events and is well studied for its role in support of retrograde transport (Lee et al., 2004 mut cells displayed signs of elevated lysosomal flux, strongly suggests that this molecular subtype requires consumption and hydrolysis of extracellular macromolecules for minimal supply of cellular metabolic intermediates. Recognition of lysosomal function as a contextdependent metabolic bottleneck is reinforced by three additional recent observations. First, the coupling of lysosome acidification capacity to mitochondrial health has been defined as a key determinant of cellular aging in yeast (Hughes and Gottschling, 2012) . Second, pancreas cancer cells mount an adaptive response to glutamine starvation by induction of macropinocytosis and consequent consumption of extracellular macromolecules as an amino-acid supply route (Commisso et al., 2013) . Third, dysregulation of mTORC1 drives addiction to versus HBEC30KT and others (n = 14). Area under the curve (AUC) was estimated by the sum of % viability over testing doses. One-sided two-sample K-S tests were performed to discriminate compounds with selective activity. K-S test p values in negative log scale were used to generate the plot. (B) HCC44 cells, transfected with the indicated siRNAs were stained with the indicated dyes and antibodies. Seventy-one percent of siARCN1 cells were Lysotracker negative versus 3.0% of siNC cells; p value < 2.2 x 10 À16 ; Fisher's exact test.
(C) Confocal imaging of mitochondrial morphology after 42 hr exposure to vATPase inhibitors. Ninety-two percent of bafA-treated and 85% saliPhe-treated cells had dysmorphic mitochondria versus 2.7% with DMSO; p value < 2.2 x 10 À16 for both; Fisher's exact test. Error bars indicate ± SEM. See also Figure S6 and Table S5 .
consumption of exogenous desaturated lipids to support endomembrane expansion (Young et al., 2013) . The incidence of cooccurring KRAS and LKB1 mutations in NSCLC is estimated to be 6% of all lung adenocarcinomas, which corresponds to 5,000 new cancer patients per year in the USA alone. Establishing KRAS mut /LKB1 mut mutation status as a robust indicator of COPI addiction presents the opportunity to exploit clinical laboratory-based detection of somatic alterations in these genes as an enrollment biomarker to stratify patient populations predicted to respond to chemical perturbation of lysosome maturation. (F) Dose-response curves for a predicted sensitive cell line, HCC2429, and a predicted resistant cell line, H1770, based on the expression signature-derived scoring function. Error bars indicate ± SD, n = 3. See also Figure S7 and Data S3-1, S3-2, S3-3, and S7.
Screening of a large diversity-based collection of synthetic small molecules revealed a chemical liability in cancer cell lines that share distinct gene-expression features. Although the target of this compound remains to be defined, the mode-of-action appears to be through selective mobilization of the unfolded protein response and consequent cell death. Of interest, a relatively large but highly selective cohort is responsive to the indolotriazine SW044248 (24% of cell lines tested). Thus, SW044248 can be described as a chemical discriminator of a distinct NSCLC subtype. If indolotriazine sensitivity is preserved in the in vivo setting, this chemical discriminator becomes a lead for therapeutically relevant pharmacological characterization of discrete vulnerabilities within this subtype.
In summary, cell-based exploration of lung cancer intervention opportunities can be a rich source of target discovery given sufficient commonality of sensitivity and resolution of molecular correlates. Starting with disease-cell-selective vulnerabilities present in isolates from a single lung cancer patient, two distinct molecular targets were identified, linked to two distinct genetic lesions, which together are represented in over 25% of lung adenocarcinoma patients. In addition, a chemically defined vulnerability was identified that is associated with an expression-based biomarker estimated to occur in 10% of lung cancer patients.
EXPERIMENTAL PROCEDURES
Materials, procedures, and computational analysis including deep sequencing, high-throughput screening, and associated data processing and analysis; mouse xenograft studies, mitochondrial respiratory potential, metabolic flux, pharmacokinetic analysis, and elastic net regression modeling; and other statistical processing protocols are detailed in the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven figures, five tables, and seven data sets and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2013.09.041.
